卡维他洛固体分散体的研制及其体外溶出实验

目的：制备卡维他洛固体分散体,增加其溶解度和溶出速度。方法：以聚乙烯吡咯烷酮（PVP）、聚乙二醇-6000（PEG-6000）为载体,溶剂法和溶剂熔融法制备固体分散体,并进行体外溶出度研究。结果：载体比例越大,药物溶出愈快;且载体比例愈小,差异愈显著。载体为PVP所制固体分散体的体外溶出行为总体优于载体为PEG-6000的固体分散体。结论：本试验所制卡维地洛固体分散体能加速体外溶出,为难溶于水药物提高生物利用度开辟一条途径。     

阿西美辛固体分散体的制备和溶出度测定

目的:利用固体分散技术制备阿西美辛固体分散体,增加其溶解度和溶出速度.方法:以聚乙烯吡咯烷酮(PVP)、聚乙二醇-6000(PEG-6000)、聚乙二醇-12000(PEG-12000)为载体,溶剂法和溶剂熔融法制成阿西美辛固体分散体,并进行体外溶出度研究.结果:载体比例越大,药物溶出越快;且载体比例越小,差异越显著.载体为PVP所制固体分散体的体外溶出总体优于载体为PEG-6000和PEG-12000的固体分散体.结论:固体分散体能加速阿西美辛体外溶出.     

卡维地洛固体分散体的制备与溶出度测定

目的：制备卡维地洛固体分散体,增加其溶解度和溶出速度。方法：以聚乙烯吡咯烷酮（PVP）、聚乙二醇－6000（PEG－6000）为载体,溶剂法和溶剂熔融法制备固体分散体,并进行体外溶出度研究。结果：载体比例越大,药物溶出愈快;且载体比例愈小,差异愈显著。载体为PVP所制固体分散体的体外溶出为总体优于载体为PEG－6000的固体分散体。结论：本试验所制卡维地洛固体分散体能加速体外溶出,为难溶于水药物提高生物利用度开辟一条途径。     

浙贝提取物固体分散体的制备及溶出特性研究

目的：制备浙贝提取物固体分散体,考察其中贝母素甲及贝母素乙的溶出效果,从而确定制备的最佳方法和最佳比例。方法：选择聚乙二醇6000（PEG6000）与聚乙烯吡咯烷酮（PVP K30）两种载体材料,分别采用熔融法和溶剂法制备浙贝提取物固体分散体;通过比较提取物、固体分散体的溶出性能,确定最佳工艺。结果：使用HPLC-ELSD法测定贝母素甲及贝母素乙的溶出量,结果准确、可靠、稳定。制备成固体分散体能显著提高贝母素甲及贝母素乙的体外溶出速度;PEG6000作为载体的浙贝提取物固体分散体溶出速度快于PVP K30为载体的浙贝提取物固体分散体。结论：以PEG6000为载体,采用熔融法制备的药物/载体比例为1∶6的固体分散体能显著提高浙贝提取物中贝母素甲及贝母素乙的溶出速率。     

卡维地洛固体分散体的制备及其体外溶出度的测定

目的 :制备卡维地洛固体分散体 ,提高其溶解度和溶速率。方法 :以聚乙烯吡咯烷酮 (PVP)、聚乙二醇 -6000(PEG -6000)为载体 ,以溶剂法和熔融法制备固体分散体 ,并进行体外溶出度研究。结果 :载体比例越大 ,药物溶出愈快 ;载体比例愈小 ,差异愈显著。载体为PVP所制固体分散体的体外溶出行为总体优于载体为PEG -6000的固体分散体。结论 :本试验所制卡维地洛固体分散体能加速体外溶出 ,提高生物利用度 ,可用于制备高效制剂     

冬凌草甲素固体分散体的制备及溶解性能研究

目的采用固体分散技术,提高冬凌草甲素的体外溶解性能。方法分别以聚乙二醇6000（PEG6000）、聚乙烯吡咯烷酮K30（PVPK30）为载体,制备冬凌草甲素固体分散体。采用紫外分光光度法进行含量测定,差示热分析法鉴别药物在载体中的存在状态,并进行溶解度、体外溶出速率实验。结果两种载体的固体分散体均能增加药物的溶解度和溶出速率,冬凌草甲素在载体中以高度分散状态存在。结论以PVPK30为载体制备的冬凌草甲素固体分散体体外溶解度和溶出速率明显提高。     

降酶灵胶囊中五味子总木脂素增溶方法的比较研究

目的验证不同工艺制备的降酶灵胶囊中五味子总木脂素的溶解度和溶出速度。方法以聚乙烯吡咯烷酮 (PVP) 为载体制备固体分散体; 以β -环糊精 (β- CD) 包合技术制备包合物, 以人工胃液为溶出介质, 紫外分光光度法测定不同制备工艺下成品的溶解度和体外溶出度。结果固体分散体的五味子总木脂素溶解度最大,与原工艺相比溶出度显著增加 (P<0. 01)。结论固体分散体有速释作用, 可考虑用固体分散技术改进降酶灵胶囊的制备工艺。     

尼群地平固体分散体的休外溶出特性

目的：制备尼群地平固体分散体,增加其溶解度和溶出速度。方法：以聚乙二醇6000（PEG6000）、聚乙二醇4000（PEG4000）、聚乙烯吡咯烷酮（PVPk30)为载体,以溶剂－熔融法和共沉淀法制备尼群地平固体分散体。应用差热分析鉴别药物在载体中的存在状态,同时进行溶解测定和溶出度研究。结果：尼群地平与载体形成了共熔物,药物以微细结晶存在于载体中,载体比例越大,药物溶出越快,溶解度越大,结论：尼群地平与3种载体形成的固体散全在水中的溶解度均有显著增加（P＜0．05）。当尼群地平－载体比例达1：4时,尼群地平从固体分散体中的溶出速度明显大于尼群地平纯药和尼发群地平－载体（1：8）物理混合物（P＜0．05）。3种载体中以PVPK30对尼群地平的溶解度及溶出速度增加最为显著。     

固体分散技术提高黄芩提取物溶出度的研究

目的：通过制备固体分散体，提高黄芩提取物的溶出度。方法：采用熔融法和溶剂法，制备聚乙二醇4000（PEG4000），聚乙二醇6000（PEG6000），聚乙烯吡咯烷酮K30（PVPK30）3种载体材料及不同比例条件下的固体分散体。通过比较原药材、固体分散体、机械混合物的溶出性能，从而确定制备的最佳方法和最佳比例。结果：不同载体不同比例的固体分散体均能提高药物的溶出度，且载体比例越大，药物的溶出越快，3种载体的增溶效果依次为PVPK30〉PEG4000〉PEG6000。结论：以PVP为载体，采用溶剂法所制备的药物/载体比例为1：6的固体分散体能显著提高黄芩提取物的溶出速率。     

固体分散技术与包合技术对吡罗昔康溶出度的影响

目的 考察固体分散技术及包合技术对吡罗昔康溶出度的影响。方法 以聚乙烯吡咯烷酮(PVP)为载体制备固体分散体；以β-环糊精(β-CD) 包合技术制备包合物。以差示扫描量热法（DSC）鉴定吡罗昔康在体系中的存在形态；以水为溶出介质, 紫外分光光度法测定不同制备工艺下成品的体外溶出度。结果 差热分析图谱表明，吡罗昔康β-CD包合物以及吡罗昔康-PVP（1：6，1：8）的固体分散体中药物以非晶型存在，而吡罗昔康-PVP（1：2，1：4）的固体分散体中，药物与载体形成低共熔物，药物以微晶形式存在于载体中；体外溶出结果表明环糊精包合物和载药比为1：6，1：8的固体分散体的溶出速率与相应物理混合物及原料药间差异有极显著性（P<0.01）。结论 制成固体分散体和β-环糊精包合物均能显著提高吡罗昔康的溶出速率。     

TOXIC AND CARCINOGENIC EFFECTS OF PARENTERAL AND PERCUTANEOUS ATP AND ITS IRON COMPLEX

ABSTRACT

The long term effects of percutaneous, subcutaneous and intraperitoneal administration of sodium–ATP (NaATP) and ferric iron–ATP (FeATP) were studied on an animal model. Both compounds induce a generalized lymphoadenitis which in the case of FeATP led to lymphomas. The analytical study of the involved target tissues showed intracellular composition changes that result from the impairment of the cell membrane permeability. The morbidity and mortality rate were higher with FeATP which seems to be the result of two different, in intensity and duration, interactions with the cell plasma membrane. The influence of the changes in cellular calcium homeostasis, and its relationship with carcinogenesis and immuno response are discussed.     

苦参碱及氧化苦参碱的药代动力学与药效动力学

以QTc延长率为效应指标,用药代动力学-药效动力学结合模型对苦参碱、氧化苦参碱iv后在免体内的处置和效应动力学作定量分析,两药的血浓时程均符合二房室模型,两药的效应与效应室浓度之间的关系均符合S形E_max模型。两药彼此的药动学和药效学性质均有明显差异,但它们各自的劳动学和药效学性质在所用剂量范围内均为非剂量依赖性。     

LIVER ALCOHOL AND ALDEHYDE DEHYDROGENASE: INHIBITION AND POTENTIATION BY HISTAMINE AGONISTS AND ANTAGONISTS

1. The in vitro effects of histamine, some other Hi- and H₂-receptor agonists and some antagonists were studied on the specific activities and kinetics of rat liver alcohol dehydrogenase (ADH), and cytoplasmic and mitochondrial liver aldehyde dehydrogenase (ALDH). 2. Histamine (H₁- and H₂-agonist) non-competitively inhibited ADH and ALDH, 2-(2-aminoethyl) pyridine (Hi-receptor agonist) non-competitively inhibited ADH. There were no changes of cytoplasmic and mitochondrial liver ALDH activities in the presence of 2-(2-aminoethyl) pyridine. 3. Betazole (H₂-receptor agonist) produced a competitive inhibition of mitochondrial ALDH but not of ADH or cytoplasmic ALDH. 4. Diphenhydramine (H₁-receptor antagonist) non-competitively inhibited ADH at a lower concentration. It stimulated mitochondrial ALDH activity without changes in cytoplasmic ALDH from control values. 5. Burimamide (H₂-receptor antagonist) produced a biphasic and dose-dependent stimulation and non-competitive inhibition of ADH and it non-competitively inhibited ALDH in both cytoplasmic and mitochondrial fractions. Metiamide (H₂-receptor antagonist) non-competitively inhibited all ADH and ALDH of both liver fraction studied. 6. It is concluded that liver ADH and ALDH activity can be altered by compounds which affect both Hi- and H₂-histamine receptors and that these compounds may cause an in vivo potentiation and/or reduction of the toxic effect of ethanol.     

TOXICOKINETICS AND EFFECTS OF FIBROUS AND NONFIBROUS PARTICLES

Chronic inhalation of fibrous and nonfibrous particles by rats at high concentrations results in lung tumor formation if the particles are poorly soluble in the lung. Even rather benign nonfibrous particles such as TiO 2 produce this result. One significant change during a chronic inhalation exposure of poorly soluble particles of low cytotoxicity (PSP) is an impairment of normal clearance mechanisms in the alveolar region of the lung in rats, resulting in a continued buildup to high lung burdens accompanied by chronic alveolar inflammation, fibrosis, and mutational events. Since these are obviously high-dose effects, questions about their extrapolation to humans exposed to much lower concentrations have been raised. Results of key studies reported for chronic inhalation of PSP in rats indicate that mechanisms of PSP-induced lung tumors at high doses do not operate at low dose levels. Furthermore, the existence of two thresholds can be postulated: One is a dosimetric threshold for the endpoint alveolar macrophage-mediated clearance, which is related to lung particle overload. The other is a mechanistic threshold for the endpoint mutation, which is determined by the level of antioxidant defenses to counter-balance reactive oxidant species released by activated inflammatory cells. A no-observed-adverse-effect level (NOAEL) could therefore be based on avoiding alteration of the toxicokinetic of the particles such that the lung burdens stay below the dosimetric threshold. The suggestion that PSP-associated organic compounds (e.g., diesel particulate matter) contribute to the lung tumor responses in rats observed in chronic inhalation studies is not supported by experimental data from in vivo studies. It can be concluded that high-dose rat lung tumors due to PSP should not be used for low-dose extrapolations, and no significant contribution to human lung cancer risk can be predicted from levels of PSP below lung overload. With respect to the pulmonary toxicokinetics of inhaled fibrous particles, the biopersistence of long fibers (>20 µm) which cannot be phagocytized by alveolar macrophages is a key parameter related to long-term carcinogenic effects. Long fibers with a very low biopersistence should not be considered as carcinogenic. Since the clearance kinetics of fibers can generally be described by a biphasic or multiphasic pattern - fast initial and slow final phase - it is essential that the slow phase of the retention kinetics of fibers longer than 20 µm is considered in a biopersistence assay. Based on the results of such assay, fibers can be classified into one of two categories: a biopersistent fiber that cannot be dissolved in the lung within an acceptable time period; or a biosoluble fiber when even long nonphagocytizable fibers will be disappearing rapidly from the lung. However, in addition to biopersistence, it should be mandatory to evaluate fiber toxicity in an appropriate assay relative to a fiber whose long-term effects are well known. Moreover, for organic fibers it is likely that different rules may have to be established for characterization of their toxic and carcinogenic potential.     

珍珠母贝中糖胺聚糖的提取分离纯化

目的:对马氏珍珠母贝中提取、分离得到的糖胺聚糖(glycosam inog lycans,GAG)进行化学组分研究。方法:样品经还原、水解和乙酰化,采用气相色谱-质谱法定性测定。结果:测定出马氏珍珠母贝中经提取、分离得到的GAG中的3种主要成分,其骨架结构分别与(硫酸乙酰)肝素、(硫酸)软骨素和透明质酸相符。结论:马氏珍珠母贝中提取分离的糖胺聚糖中含有肝素、软骨素和透明质酸。     

HPLC和~1HNMR分析确定cis－A－和cis－B－羟甲芬太尼的组成和构型

羟甲芬太尼（１）是一个强效的镇痛剂和高亲和、高选择性的阿片μ受体激动剂。通过ＨＰＬＣ和１ＨＮＭＲ分析，ｃｉｓ－Ａ－ｌ被确定为由等量的ｃｉｓ－（＋）－（３Ｒ，４Ｓ，２＇Ｓ）－ｌ和：ｃｉｓ－（—）－（３Ｓ，４Ｒ，２＇Ｒ）－１组成的外消旋体，ｃｉｓ－Ｂ－ｌ被确定为由等量的ｃｉｓ－（—）－（３Ｒ，４Ｓ，２＇Ｒ）－１和ｃｉｓ－（＋）－（３Ｓ，４Ｒ，２＇Ｓ）－１组成的外消旋体。     

SODIUM AND NORADRENALINE IN CEREBROSPINAL FLUID AND BLOOD IN SALT-SENSITIVE AND NON-SALT-SENSITIVE ESSENTIAL HYPERTENSION

1. The effects of dietary sodium on blood pressure and levels of sodium, other electrolytes and noradrenaline (NA) in the cerebrospinal fluid (CSF) and blood of 15 patients with essential hypertension were studied. The CSF and blood sampling was carried out after 7 days of a high salt intake (16-18 g/day) and after 7 days of a low salt intake (1-3 g/day). 2. Blood pressure and sodium concentrations in CSF and serum were significantly higher in the high salt period than the low salt period (CSF Na+ concentration: 147.7 +/- 0.4 mmol/L vs 145.3 +/- 0.5 mmol/L; P less than 0.001). Levels of CSF pressure and potassium or calcium concentrations were not different between the two periods. Plasma NA and plasma renin activity (PRA) were lower and CSF NA levels tended to be lower in the high salt period. 3. The levels and the changes in sodium and NA in CSF were not significantly different between the salt-sensitive (n = 8) and the non-salt-sensitive (n = 7) subjects, but the changes in plasma NA and PRA were smaller in the salt-sensitive subjects. 4. These results indicate that the sympathetic nervous system is less suppressed in salt-sensitive subjects during high salt intake. This may be due to altered neural responsiveness to sodium loading rather than being greater increases in sodium concentration in the central nervous system.     

冰毒吸食者焦虑抑郁情绪和自我概念的测评及相关分析

目的:了解冰毒吸食者焦虑抑郁情绪和自我概念状况,探讨二者之间的关系,为临床心理干预提供依据。方法:采用抑郁自评量表(SDS),焦虑自评量表(SAS)和田纳西自我概念量表(TSCS)对36例强制戒毒的冰毒吸食者(研究组)和36例健康人群(对照组)进行调查,将结果进行统计学处理分析。结果:(1)研究组SDS,SAS评分明显高于对照组,差别具有统计学意义(P<0.01);(2)TSCS评分比较,研究组除自我批评因子分高于对照组外,其余各因子分均低于对照组,差异具有统计学意义(P<0.01);(3)TSCS与SAS和SDS之间具有高度相关性(r=0.411-0.462,P<0.01)。结论:冰毒吸食者焦虑抑郁情绪明显,表现为消极的自我概念;焦虑抑郁情绪影响自我概念。临床治疗中应关注戒毒者负性情绪和自我概念,采取有效措施帮助他们消除负性情绪,树立积极的自我概念,促进心理康复。